A-30912A Nucleus
AssigneeEli Lilly and Company
InventorsBernard J. Abbott, David S. Fukuda
Life of this patent
Estimating the term…
Abstract
A-30912A nucleus, which is prepared by enzymatic deacylation of an antibiotic selected from A-30912 factor A, tetrahydro-A-30912A, and aculeacin A using an enzyme produced by the Actinoplanaceae, preferably by Actinoplanes utahensis. A-30912A nucleus and salts thereof are useful intermediates to prepare new semi-synthetic antifungal agents.
Claims22
A-30912A nucleus of the formula ##STR30## and the acid addition salts thereof.
The method of deacylating an antibiotic selected from the group consisting of A-30912 factor A, tetrahydro A-30912A, and aculeacin A which comprises exposing the antibiotic in an aqueous medium to an enzyme which deacylates and which is produced by a microorganism of the family Actinoplanaceae until substantial deacylation is accomplished.
Dependencies are inferred from the claim text.